and btw great point @AppleHelix first prize commercially is a co-formulation with a biosimilar:
69
$KOD ugly BCVA fail on EFFICACY - v. good news for eylea and $REGN @John_Hempton @sentivcapital but one outlier program STILL off radar of everyon that is all about EFFICACY/superiority in combo: Opthea $OPT :)
Replying to @TangibleIM @sentivcapital
love this chart too @sentivcapital - looking frwd to what it looks like at 12 months and alongside eylea $OPT
Valuation of $UPST against its more seasoned profitable highly-regulated Chinese peers $QFIN $LX $FINV 😱 youtube.com/watch?v=2DH4v6Fn…
Replying to @ByMadeleineA
@ByMadeleineA @sentivcapital Granted n=1 and lower dose POC trial but this is amazing news from Gensight Biologics $SIGHT: youtube.com/watch?v=iHP2s1WS…
1
Replying to @jq1234t @brendan_49







